EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

Qingjian He, Junling Lin, Chanjuan Mo, Guodong Li, Jianzhong Lu, Qiyin Sun, Lijun Cao, Haojian Gan, Quan Sun, Jiafang Yao, Shengyi Lian, WenJuan Wang

Frontiers in Pharmacology · 09.01.2025 · 15

DOI: 10.3389/fphar.2024.1463520 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.01.2025. Verfasst von Qingjian He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University, Huzhou, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase inhibitors (TKIs), are extensively employed as VEGF inhibitors; however, they are also associated with a higher incidence of complications, with hypertension being the most prevalent cardiovascular toxic side effect. Currently, it is widely accepted that TKIs-induced hypertension involves multiple mechanisms including dysregulation of the endothelin (ET) axis, reduced bioavailability of nitric oxide (NO), imbalance in NO-ROS equilibrium system, vascular rarefaction, and activation of epithelial sodium calcium channels; nevertheless, excessive activation of ET system appears to be predominantly responsible for this condition. Moreover, studies have demonstrated that ET plays a pivotal role in driving TKIs-induced hypertension. Therefore, this review aims to explore the significance of ET in the pathogenesis of hypertension induced by targeted anti-tumor drugs and investigate the potential therapeutic value of endothelin antagonists in managing hypertension caused by targeted anti-tumor drugs.

Schlagwörter

Stichwörter der Autor:innen

aprocitentanendothelinendothelin receptor antagonistshypertensiontyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University, Huzhou, China.
  • Department of Cardiovascular Center, First Affiliated Hospital of Huzhou University, Huzhou, China.
  • School of Medicine, Huzhou University, Huzhou, China.

Zitieren

APA

He, Q., Lin, J., Mo, C., Li, G., Lu, J., Sun, Q., Cao, L., Gan, H., Sun, Q., Yao, J., Lian, S., & Wang, W. (2025). Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs). Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1463520

Vancouver

He Q, Lin J, Mo C, Li G, Lu J, Sun Q, et al. Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs). Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1463520

BibTeX
@article{He2025,
  author = {He, Qingjian and Lin, Junling and Mo, Chanjuan and Li, Guodong and Lu, Jianzhong and Sun, Qiyin and Cao, Lijun and Gan, Haojian and Sun, Quan and Yao, Jiafang and Lian, Shengyi and Wang, WenJuan},
  title = {Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fphar.2024.1463520}
}
Kostenlos starten →